DE69422191T2 - A1 adenosin rezeptor agonisten und antagonisten - Google Patents
A1 adenosin rezeptor agonisten und antagonistenInfo
- Publication number
- DE69422191T2 DE69422191T2 DE69422191T DE69422191T DE69422191T2 DE 69422191 T2 DE69422191 T2 DE 69422191T2 DE 69422191 T DE69422191 T DE 69422191T DE 69422191 T DE69422191 T DE 69422191T DE 69422191 T2 DE69422191 T2 DE 69422191T2
- Authority
- DE
- Germany
- Prior art keywords
- antagonists
- receptor agonists
- adenosine receptor
- adenosine
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/144,459 US5446046A (en) | 1993-10-28 | 1993-10-28 | A1 adenosine receptor agonists and antagonists as diuretics |
PCT/US1994/012388 WO1995011904A1 (en) | 1993-10-28 | 1994-10-28 | Novel a1 adenosine receptor agonists and antiagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69422191D1 DE69422191D1 (de) | 2000-01-20 |
DE69422191T2 true DE69422191T2 (de) | 2000-05-25 |
Family
ID=22508686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69422191T Expired - Lifetime DE69422191T2 (de) | 1993-10-28 | 1994-10-28 | A1 adenosin rezeptor agonisten und antagonisten |
Country Status (13)
Country | Link |
---|---|
US (3) | US5446046A (de) |
EP (1) | EP0725782B1 (de) |
JP (2) | JP3677286B2 (de) |
KR (2) | KR100337269B1 (de) |
AT (1) | ATE187726T1 (de) |
AU (1) | AU699630B2 (de) |
CA (1) | CA2172726C (de) |
DE (1) | DE69422191T2 (de) |
DK (1) | DK0725782T3 (de) |
ES (1) | ES2141913T3 (de) |
GR (1) | GR3032730T3 (de) |
PT (1) | PT725782E (de) |
WO (1) | WO1995011904A1 (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
US5736528A (en) * | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
US5591776A (en) | 1994-06-24 | 1997-01-07 | Euro-Celtique, S.A. | Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
DE69531555T2 (de) | 1994-12-13 | 2004-06-17 | Euroceltique S.A. | Dreifachsubstituierte thioxanthine |
CA2206287C (en) | 1994-12-13 | 2001-03-20 | Mark Chasin | Aryl thioxanthines |
US6166041A (en) | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
US6075016A (en) | 1996-04-10 | 2000-06-13 | Euro-Celtique S.A. | 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity |
US5864037A (en) | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
US5789416B1 (en) * | 1996-08-27 | 1999-10-05 | Cv Therapeutics Inc | N6 mono heterocyclic substituted adenosine derivatives |
TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
JP2002505687A (ja) | 1997-06-18 | 2002-02-19 | ディスカバリー セラピューティクス,インコーポレイテッド | 脈管再生手順の後の再狭窄を防止するための組成物および方法 |
YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
EP0994711B1 (de) * | 1998-04-24 | 2003-10-29 | Biogen, Inc. | Adenosin a1 rezeptor antagonisten enthaltende zusammensetzung und verfahren zur wiederherstellung der diuretischen- und nierenfunktion |
US20020115687A1 (en) * | 1998-04-24 | 2002-08-22 | Evan Beckman | Method and composition for restoring diuretic and renal function |
EP1386609A1 (de) * | 1998-04-24 | 2004-02-04 | Cv Therapeutics | Adenosin A1 Rezeptor Antagonisten enthaltende Zusammensetzung und Verfahren zur Wiederherstellung der Diuretischen- und Nierenfunktion |
US6060481A (en) * | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
ID29609A (id) | 1998-06-23 | 2001-09-06 | Glaxo Group Ltd | Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US6576619B2 (en) | 1999-05-24 | 2003-06-10 | Cv Therapeutics, Inc. | Orally active A1 adenosine receptor agonists |
US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
AU784556B2 (en) * | 1999-11-12 | 2006-05-04 | Biogen Idec Ma Inc. | Polycycloalkylpurines as adenosine receptor antagonists |
WO2001034604A2 (en) * | 1999-11-12 | 2001-05-17 | Biogen, Inc. | Adenosine receptor antagonists and methods of making and using the same |
WO2001040799A2 (en) * | 1999-12-03 | 2001-06-07 | Cv Therapeutics, Inc. | Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias |
US20050038017A1 (en) * | 1999-12-22 | 2005-02-17 | Wolff Andrew A. | Method and composition for restoring diuretic and renal function |
AU2001292591B2 (en) * | 2000-09-08 | 2004-06-03 | Gilead Palo Alto, Inc. | Purine ribosides as antiarrhythmics |
US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
US20050054596A1 (en) * | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
UA80258C2 (en) * | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
WO2003029264A2 (en) * | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US20080318983A1 (en) * | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
AU2003261206A1 (en) * | 2002-07-19 | 2004-02-09 | Aryx Therapeutics | Xanthine derivatives having adenosine a1-receptor antagonist properties |
US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
BRPI0409699A (pt) * | 2003-04-25 | 2006-04-18 | Novacardia Inc | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos |
US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
EP1932529A1 (de) | 2003-04-25 | 2008-06-18 | Novacardia, Inc. | Verfahren zur verbesserten Harnausscheidung bei Personen mit beeinträchtiger Nierenfunktion |
BRPI0509753A (pt) * | 2004-04-16 | 2007-10-16 | Novacardia Inc | composição farmacêutica e método de tratamento de doença cardiovascular |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
WO2006023272A1 (en) * | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
US7576069B2 (en) * | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
NZ553288A (en) * | 2004-08-02 | 2010-12-24 | Univ Virginia | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
NZ553487A (en) * | 2004-09-01 | 2010-09-30 | Gilead Palo Alto Inc | Method of wound healing using A2B adenosine receptor antagonists |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
US20070059740A1 (en) * | 2005-08-26 | 2007-03-15 | Linden Joel M | Method of targeting a2b adenosine receptor antagonist therapy |
WO2007120972A2 (en) * | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
EP2035009A1 (de) * | 2006-06-16 | 2009-03-18 | Novacardia, Inc. | Dauerhafte verbesserung der nierenfunktion mit seltener verabreichung eines aa1ra |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
US8193200B2 (en) * | 2007-01-04 | 2012-06-05 | University Of Virginia Patent Foundation | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease |
WO2008121893A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
US20080242684A1 (en) * | 2007-03-29 | 2008-10-02 | Howard Dittrich | Methods of administration of adenosine a1 receptor antagonists |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
CN102014959B (zh) | 2008-03-10 | 2016-01-20 | 康奈尔大学 | 血脑屏障通透性的调节 |
US20130109645A1 (en) | 2010-03-31 | 2013-05-02 | The united States of America,as represented by Secretary,Dept.,of Health and Human Services | Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders |
DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2460929A1 (de) * | 1974-12-21 | 1976-06-24 | Boehringer Sohn Ingelheim | Neue xanthinderivate, verfahren zu ihrer herstellung und ihre anwendung |
US4364922A (en) * | 1980-10-14 | 1982-12-21 | University Of Virginia Alumni Patents Foundation | Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances |
DE3138397A1 (de) * | 1981-09-26 | 1983-04-07 | Hoechst Ag, 6230 Frankfurt | "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen" |
US4980379A (en) * | 1988-06-30 | 1990-12-25 | The University Of Virginia | Use of adenosine antagonists in the treatment of bradyarrhythmias and hemodynamic depression associated with cardiopulmonary resucitation and/or cardiovascular collapse |
DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
DE4205306B4 (de) * | 1992-02-21 | 2005-11-24 | Glüsenkamp, Karl-Heinz, Dr. | Säureamide, Arzneimittel mit denselben und Verfahren zur Herstellung von Säureamiden |
AU5138493A (en) * | 1992-09-22 | 1994-04-12 | Cell Therapeutics, Inc. | Novel epoxide-containing compounds |
US5288721A (en) * | 1992-09-22 | 1994-02-22 | Cell Therapeutics, Inc. | Substituted epoxyalkyl xanthines |
WO1994016702A1 (en) * | 1993-01-26 | 1994-08-04 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for irregular bowel movement |
US5446046A (en) * | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
-
1993
- 1993-10-28 US US08/144,459 patent/US5446046A/en not_active Expired - Lifetime
-
1994
- 1994-10-28 CA CA002172726A patent/CA2172726C/en not_active Expired - Fee Related
- 1994-10-28 AU AU10449/95A patent/AU699630B2/en not_active Ceased
- 1994-10-28 PT PT95901070T patent/PT725782E/pt unknown
- 1994-10-28 EP EP95901070A patent/EP0725782B1/de not_active Expired - Lifetime
- 1994-10-28 WO PCT/US1994/012388 patent/WO1995011904A1/en active Application Filing
- 1994-10-28 KR KR1019960702164A patent/KR100337269B1/ko not_active IP Right Cessation
- 1994-10-28 US US08/330,640 patent/US5631260A/en not_active Expired - Lifetime
- 1994-10-28 DE DE69422191T patent/DE69422191T2/de not_active Expired - Lifetime
- 1994-10-28 DK DK95901070T patent/DK0725782T3/da active
- 1994-10-28 JP JP51285795A patent/JP3677286B2/ja not_active Expired - Fee Related
- 1994-10-28 KR KR10-2001-7015426A patent/KR100401454B1/ko not_active IP Right Cessation
- 1994-10-28 ES ES95901070T patent/ES2141913T3/es not_active Expired - Lifetime
- 1994-10-28 AT AT95901070T patent/ATE187726T1/de active
-
1995
- 1995-06-06 US US08/470,113 patent/US5668139A/en not_active Expired - Lifetime
-
2000
- 2000-02-23 GR GR20000400429T patent/GR3032730T3/el unknown
-
2001
- 2001-07-26 JP JP2001225995A patent/JP3892254B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE187726T1 (de) | 2000-01-15 |
PT725782E (pt) | 2000-05-31 |
CA2172726A1 (en) | 1995-05-04 |
EP0725782B1 (de) | 1999-12-15 |
US5446046A (en) | 1995-08-29 |
JP2002105094A (ja) | 2002-04-10 |
KR100401454B1 (ko) | 2003-10-17 |
DE69422191D1 (de) | 2000-01-20 |
GR3032730T3 (en) | 2000-06-30 |
JP3892254B2 (ja) | 2007-03-14 |
AU699630B2 (en) | 1998-12-10 |
DK0725782T3 (da) | 2000-06-13 |
JPH09507052A (ja) | 1997-07-15 |
KR100337269B1 (ko) | 2002-11-11 |
EP0725782A1 (de) | 1996-08-14 |
US5668139A (en) | 1997-09-16 |
ES2141913T3 (es) | 2000-04-01 |
AU1044995A (en) | 1995-05-22 |
WO1995011904A1 (en) | 1995-05-04 |
CA2172726C (en) | 2004-01-13 |
JP3677286B2 (ja) | 2005-07-27 |
US5631260A (en) | 1997-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE187726T1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
DE69626705D1 (de) | A1 adenosin rezeptor agonisten und antagonisten | |
TR200103607T2 (tr) | Pürin Türevleri | |
DE69428536D1 (de) | A3 -adenosin -rezeptor agonisten | |
TR200201001T2 (tr) | Pürin türevleri | |
TR200200985T2 (tr) | Pürin türevleri | |
BR9707136A (pt) | Derivados morfinóides condesados em heterociclo (ii) | |
WO1999064401A3 (en) | Imidazolyl derivatives and their use as somatostatin receptor ligands | |
EA200101177A1 (ru) | Производные индола в качестве антагонистов прогестерона | |
ES2175079T3 (es) | Derivados de indol utiles como inhibidores de cgmp-pde. | |
ES2054872T3 (es) | Nuevos derivados de acido bencimidazolin-2-oxo-1-carboxilico utiles como antagonistas de los receptores 5-ht. | |
MX9205046A (es) | 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas | |
ATE254456T1 (de) | Cannabinoid-rezeptor-antagonisten | |
WO2000073307A8 (en) | Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors | |
ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
TR199902848T2 (xx) | Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar� | |
ES2060818T3 (es) | Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa. | |
TR200301062T2 (tr) | Adenosin reseptörü antagonistleri ve bu antagonistlerin yapım ve kullanım yöntemleri | |
ES507807A0 (es) | Procedimiento para la obtencion de derivados triciclicos de citosina. | |
IL79264A0 (en) | Tryptamine derivatives,pharmaceutical compositions containing them and their use in an assay for melatonin receptors | |
ES2120025T3 (es) | Derivados de xantina utilizados como antagonistas de receptores de adenosina a1. | |
TR199901380A2 (xx) | Di-ya da triazo-spiro$4,5] dekan t�revleri | |
DE69004455T2 (de) | Alpha-adrenergene Rezeptor-Antagonisten. | |
IT1270611B (it) | Derivati eterociclo-condensati di morfinoidi | |
DE69004827T2 (de) | Alpha-adrenergene Rezeptor-Antagonisten. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |